AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05708573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: In Treatment Period 1, participants will receive a single oral tablet of rosuvastatin in the morning of Day 1. In treatment period 2, on the morning of Day 4, participants will receive a single 20 mg dose of rosuvastatin (co-administered with the morning dose of ALXN2040).
Study NCT05708573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN2040
Description: In Treatment Period 2, participants will receive oral tablets of ALXN2040 three times daily on Days 1 through 7.
Study NCT04966624 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LUVS ventilatory strategy composed of a bundle of measures
Description: Ventilation in APRV mode early prone sessions, adjustment of positive expiratory pressure according to the patient's BMI and no curarization
Study NCT04966624 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
Description: Ventilatory management according to international recommendations (Société de Réanimation de la Langue Française)
Study NCT05232214 — intervention group
Intervention type: DEVICE
Intervention: Biometry
Description: Only one eye from each patient will be included in the study. All patients included in the study will undergo biometric measurements in a random fashion with the three devices (IOLMaster 700, Argos and Anterion Heildelberg). Each patient will be measured three times with each device
Study NCT06367660 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal Bupivacaine-Fentanyl and Bupivacaine-Dexmedetomidine
Description: In patients undergoing elective LSCS under subarachnoid block, group BF will receive 0.5% hyperbaric bupivacaine 10mg (2ml) with fentanyl 10 mcg (0.2ml) with total of 2.2 ml and group BD will receive 0.5% hyperbaric bupivacaine 10 mg with Dexmedetomidine 5mcg (0.2ml) total volume 2.2ml. Assessment of intraoperative visceral pain will be done by self-reporting of patients, who are previously educated, as poorly localized discomfort or dragging, pulling heaviness or unpleasant feeling or pain with or without nausea and will be categorized according to preformed scale.
Study NCT04091594 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible orthotic
Description: Participants will receive the SIAFO to wear
Study NCT04091594 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard orthotic
Description: Participants will received the standard AFO to wear
Study NCT06554600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: 160mg bid PO（d0-d20）
Study NCT06554600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin on Day 2 of each cycle.
Study NCT06554600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 70 mg/m2 Bendamustine on Days 2 and 3 of each cycle.
Study NCT06554600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a total of 4-6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab on Day 1 of each cycle.
Study NCT05334472 — intervention group
Intervention type: OTHER
Intervention: Kesimpta
Description: There was no treatment allocation. Patients administered Kesimpta by prescription that started before inclusion of the patient into the study were enrolled.
Study NCT05265858 — intervention group
Intervention type: PROCEDURE
Intervention: Total Hip Arthroplasty
Description: Direct Anterior Approach (DAA) Total Hip Arthroplasty (THA)
Study NCT04633369 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dietary fibers
Description: during days 13-22 the participants will consume the dietary fiber according to their randomization and continue fasting. Participants will be asked to collect stool and oral samples 4 times during this period.
Study NCT06388135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab Combined With Nab-paclitaxel and Cisplatin
Description: Serplulimab (200 mg), cisplatin (60-75 mg/m2), and nab-paclitaxel (135 mg/m2) administered intravenously at the beginning of every 3-week cycle.
Study NCT06513923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam
Description: In Remimazolam group, the induction dose of remimazolam is 0.3 mg/kg based on previous studies, the maintenance of anesthesia is 0.3-0.7 mg/kg/hr.
Study NCT06513923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flumazenil
Description: Immediately after the cessation of remimazolam infusion in PACU(PACU, Postanesthesia care unit), the nurses who are blind to the anesthesia management were asked to administer the flumazenil.
Study NCT06513923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: For propofol group, the induction of propofol is 1.5-2.0 mg/kg, followed by the maintenance of propofol infusion with 6-8 mg/kg/hr throughout the surgical procedure.
Study NCT01882712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD07805/47 Gel 0.5%
Study NCT01882712 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CD07805/47 Gel Placebo
Study NCT06123273 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise-oriented training
Description: IG received an exercise-oriented training with a 20-minute presentation including graphics, in line with clinical guidelines, in addition to routine recommendations. The training included information about the benefits of exercise and the harms of a sedentary life, the relationship between exercise and chronic diseases, suggestions to have a more active lifestyle and on how to exercise, the duration and form of exercise necessary for a healthy life, and the things to be considered while exercising. During the three-month follow-up, the subjects in the IG were called every two weeks to ask about their weight measurements, their level of exercise, and how much they walked. The subjects' questions, if any, were answered, and the interview was completed by making exercise suggestions.
Study NCT05677477 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation training
Description: A mother scenario with a baby with physiological jaundice will be implemented with the intervention group.
Study NCT05858476 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 21-Day Detox and Green Drink supplement
Description: Detox plan description:~7AM Water 16oz. 8AM Green Drink 16oz. 9AM Ultra Shake 16oz. 9-12PM Water 24 - 48oz. 12PM Green Drink 16oz. 12:30 - 2PM Water 24 - 48oz. 2PM Green Drink 16oz. 3PM Ultra Shake 16oz. 3:30- 6PM Water 24 - 48oz. 6PM Green Drink 16oz. 7PM Detox Soup 16oz. 7:30 - 10PM Water 24 - 48oz. This 21-day period will be followed by 7 days of consuming the Green Drink Supplement.
Study NCT02919163 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
Study NCT06388135 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: nab-paclitaxel，Cisplatin
Description: nab-paclitaxel，Cisplatin
Study NCT05376995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Graston technique
Description: Graston technique among patient of knee osteoarthritis
Study NCT05376995 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: muscle energy technique among patient of knee osteoarthritis
Study NCT05951543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plyometric exercises
Description: Experimental group will be given baseline exercises along with plyometric exercises such as Vertical jump, run and jump, drop jump (jump height between 40 and 50 cm) drop jump and horizontal jump with same height from 3rd week.particepents perform exercises carrying medicine balls. Participants will place their hands on the wall and performed foot stretches with the feet apart, 30 to 50 cm from the wall. Side row, biceps stretch and frontal row. Throwing and receiving, with a distance between 3 to 4 m.
Study NCT05951543 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dynamic balance group control group
Description: Control group will be given with the standard physical therapy intervention that includes progressive resistance training that will be performed using weights, two sets of 10 repetitions will be given for each muscle group, resistance will be increased by ½ Kg as children are able to complete without undue stresses); balance exercises (stand on a balance board, one-leg stance, heal-to-toes stance, walking on balance board, walking on a balance beam, walking on a line, and walking on the inclined surface); flexibility exercises
Study NCT06169995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam Tosilate
Description: bolus dose: 5mg，IV supplemental dose: 2.5mg，IV
Study NCT06044233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STI-1558
Description: STI-1558 test preparation and reference preparation
Study NCT06402786 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kitea ICP Sensor
Description: Kitea ICP Sensor placed in brain during shunt surgery.
Study NCT05004519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Study NCT05004519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: dexmedetomidine or remifentanil during laparoscopic gastric bypass
Study NCT05452109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction
Description: Blood flow restriction with low load (30-50% 1RM) for 2 sessions in a week for 6 weeks during classical training will be applied.
Study NCT05452109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Classical Training Alone
Description: Classical training same as Group 1with moderate to high load (70-90% 1RM) for 2 sessions in a week for 6 weeks will be applied without blood restriction.
Study NCT05296746 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribociclib (neoadjuvant)
Description: Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
Study NCT05296746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (neoadjuvant)
Description: Ribociclib 600 mg/day + letrozole during neoadjuvant phase.
Study NCT05387798 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD011
Description: Cannabidiol Oral Solution (containing synthetic cannabidiol)
Study NCT05296746 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy (adjuvant)
Description: Adjuvant chemotherapy. 3 regimens are permitted.
Study NCT05296746 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribociclib (adjuvant)
Description: Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
Study NCT05296746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib (adjuvant)
Description: Ribociclib 400 mg/day + letrozole (or other aromatase inhibitor) during adjuvant phase.
Study NCT06260449 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical removal
Description: Removal of the granuloma
Study NCT06510179 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Toothbrushing
Description: Patients brush their teeth using the technique instructed to them using the toothbrush provided.
Study NCT06510179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toothbrushing
Description: Patients brush their teeth using the technique instructed to them using the toothbrush provided.
Study NCT05274516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 tablet、placebo
Description: HRS-2261 oral tablet, oral, single dose. Matching placebo to HRS-2261, oral, single dose.
Study NCT05274516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS-2261 tablet、placebo
Description: HRS-2261 oral tablet, oral, BID. Matching placebo to HRS-2261, oral, BID.
Study NCT05068505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community health worker delivered multicomponent intervention
Description: The multi-component intervention will be centered on monthly household visits by trained CHWs for a period of seven months in a rural setting in Nakaseke, Uganda, consisting of the following; (1) blood pressure and sugar monitoring; (2) BMI monitoring; (3) cardiovascular disease risk assessment; (4) Using checklists to guide monitoring and referral to clinics; (5) healthy lifestyle counselling and education. During home visits, CHWs will remind patients of follow-up visits. We will measure blood pressure at baseline and 3-monthly for the entire cohort. We will conduct individual-level mixed effects analyses of study data, adjusting for time and clustering by patient and community.~We will conduct an interim analysis at 3 months to assess differences between groups. If a statistically significant difference is detected the intervention will be applied across the remaining clusters
Study NCT06318247 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: site preservation
Description: Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
Study NCT06318247 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: site preservation
Description: Tooth extraction of third molars with site preservation using bio-oss (0.5g, Small granule) and bio-guide (25\*25mm size). The bone graft material used in the surgical procedure was provided by Geistlich Pharma AG.
Study NCT05092113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: a compound glutamine capsule/a compound glutamine capsule simulated placebo
Description: A compound glutamine capsule/a compound glutamine capsule simulated placebo was taken orally from the first day of chemotherapy, orally 3 times a day after meals, 3 tablets each time, the course of treatment is 3 weeks.
Study NCT04745312 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Visible light
Description: Ambient room lighting will be supplemented with additional light from a task lamp.
Study NCT04745312 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visible light
Description: Ambient room lighting will be supplemented with additional light from a task lamp.
Study NCT05474989 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LSD
Description: Moderate to high dose LSD
Study NCT05474989 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active placebo
Description: Low dose LSD
Study NCT02067533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue repair in flexion position
Study NCT02067533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: soft tissue repair in extension position
Study NCT04725539 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hypoxic exposure
Description: Administration of different hypoxic doses.~Intermittent hypoxia:~days 1-5 duration of breathing periods 5\*3min (FiO2 14-21%) days 8-12 duration of breathing periods 4\*4min (FiO2 = 12%) and 3\*3 min (FiO2 = 21%) days 15-19 duration of breathing periods 5\*5min (FiO2 = 10%) and 4\*3 min (FiO2 = 21%)~one night at 1900m
Study NCT03822338 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumoperitoneum preconditioning
Description: Pneumoperitoneum preconditioning consists of three cycles of 5 min insufflation and 5 min desufflation, after complete anesthesia and successfully implanting the veress. This process will be induced by pneumoperitoneum machine, and the utilized gas will be carbon dioxide to maintain the intra-abdominal pressure at 15 mmHg. The whole duration will last 30 min.
Study NCT03822338 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham-Pneumoperitoneum preconditioning
Description: Sham-Pneumoperitoneum preconditioning consists of three cycles without insufﬂation and subsequent desufﬂation. The whole duration will also last 30 min.
Study NCT03936478 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRIdian Radiation Treatment Unit
Description: partial breast irradiation using 3 x 8.2 Gy to the lumpectomy cavity with a 3mm planning tumor volume (PTV) margin
Study NCT05503979 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir 400 MG / Velpatasvir 100 MG [Epclusa]
Description: 1 tab every 24 hrs for 12 weeks
Study NCT05537610 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CDT
Description: In this condition, the clinician will alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. According to RaC2, alternating periods of reinforcer availability and unavailability for the alternative response will teach the participant that the alternative response alone produces reinforcement but not always. The investigators predict that resurgence of problem behavior will lower, shorter lasting, and with fewer participants experiencing resurgence than those in the control group.
Study NCT05537610 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: This condition emulates a traditional approach to treatment in which the clinician does not alternate sessions with reinforcement for the alternative response and sessions without reinforcement for the alternative response during extinction treatment of problem behavior. The investigators predict that resurgence of problem behavior will higher, longer lasting, and with more participants experiencing resurgence than those in the CDT group.
Study NCT02846857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with sensor-augmented pump
Description: A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
Study NCT02846857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with single-hormone closed-loop
Description: A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
Study NCT02846857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 15-week intervention with dual-hormone closed-loop
Description: A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
Study NCT06353048 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fixation of tibial plateau fractures
Description: fixation of tibial plateau fractures by screws only versus plate and screws
Study NCT04903574 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2 sedentary behavior app
Description: This is a smartphone app that reminds you to stand up if you've been sitting for at least 30 minutes.
Study NCT04903574 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pregnancy smartphone app
Description: This is a commercially available general pregnancy smartphone app
Study NCT06216041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMM-H014
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
Study NCT02846857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin pump
Description: MiniMed® Paradigm® Veo™, Medtronic
Study NCT02846857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous glucose monitoring system
Description: Enlite sensor®, Medtronic
Study NCT06216041 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: SAD and MAD adopt sentinel method which 2 healthy subjects first will receive IMM-H014, and if are evaluated to be tolerable, the remaining 8 subjects will be randomly assigned to receive IMM-H014 and placebo in a ratio of 3:1(10 in per experimental Cohort).
Study NCT02846857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
Study NCT02846857 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucagon
Description: Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.